**Name of Journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 75419

**Manuscript Type:** LETTER TO THE EDITOR

**Insight on BRAFV600E mutated colorectal cancer immune microenvironment**

Abushukair HM *et al*. BRAFV600E-mutated colorectal cancer

Hassan Mohammed Abushukair, Sara Mu'amar Zaitoun, Anwaar Saeed

**Hassan Mohammed Abushukair,** Faculty of Medicine, Jordan University of Science and Technology, Irbid 22110, Jordan

**Sara Mu'amar Zaitoun,** Faculty of Medicine, Yarmouk University, Irbid 21163, Jordan

**Anwaar Saeed,** Department of Medicine, Division of Medical Oncology, The University of Kansas Cancer Center, Kansas City, KS 66205, United States

**Author contributions:** Abushukair HM and Zaitoun SM drafted the manuscript and contributed to conceptualization; Saeed A contributed to conceptualization of core concepts and critically revised the draft.

**Corresponding author: Anwaar Saeed, MD,** Department of Medicine, Division of Medical Oncology, The University of Kansas Cancer Center, 2330 Shawnee Mission Pkwy, Suite 210, Kansas City, KS 66205, United States. asaeed@kumc.edu

**Received:** January 27, 2022

**Revised:** May 4, 2022

**Accepted: May 21, 2022**

**Published online:**

**Abstract**

Colorectal cancer (CRC) is the second deadliest malignancy for both sexes. The BRAFV600E mutation, one of the most common driver mutations in CRC, is known for its poor prognosis due to the increased risk of metastasis. The effect of the BRAFV600E mutation on the tumor microenvironment was the topic of the study reported in *World Journal of Gastrointestinal Oncology*, with special focus on immune status. The authors presented insightful findings that were exclusively based on macrophage polarity and cytokine levels, without investigating other relevant immune elements. A more comprehensive look into the dynamic immune activity of cancer environments will warrant more meaningful practical findings. In this letter, we discuss other significant immune factors and their possible implications on the tumor microenvironment of BRAF-mutated CRC.

**Key Words:** Colorectal cancer; BRAFV600E; Tumor microenvironment; Microsatellite instability; Macrophages; Immune checkpoint proteins

Abushukair HM, Zaitoun SM, Saeed A. Insight on BRAFV600E mutated colorectal cancer immune microenvironment. *World J Gastrointest Oncol* 2022; In press

**Core Tip:** The immune landscape of the tumor microenvironment is a crucial indicator of the proliferative and invasive activity of the tumor cells and serves as a predictor of response to targeted immunotherapeutic modalities. BRAFV600E is one of the most common driver mutations in colorectal cancer thought to have a unique impact on the tumor immune microenvironment. It is unknown whether this impact is of a suppressive or activating nature. Future studies on larger samples, considering a wider array of immune elements, such as the infiltration of relevant immune cells as well as immune checkpoints’ expression, are needed.

**TO THE EDITOR**

We read the interesting study by Zhi *et al*[1] on the immune status of BRAFV600E-mutated colorectal cancer (CRC), titled “BRAFV600E mutant colorectal cancer cells mediate local immunosuppressive microenvironment through exosomal long noncoding RNAs”, in which they utilized patient tissue samples, CRC cell lines as well as in silico analysis to study correlations between the BRAFV600E mutation and changes in the local immune microenvironment of CRC. The authors reported an immunosuppressive microenvironment induced by exosomal long noncoding RNAs in BRAFV600E mutant CRC as well as higher angiogenic and lymphangiogenic activity compared to wild-type CRC.

We would like to point out the complementary findings to this study from previous work that has alluded to other parts of the immune landscape of the tumor microenvironment of BRAFV600E CRC. From this study, Zhi *et* *al*[1] reported a higher level of M2 macrophages in BRAFV600E-mutated patients compared to the wild-type, with no difference in M1 macrophages levels. Yet, the sample number from which these results were obtained was relatively small (BRAFV600E mutation: 10; BRAF wild-type: 20), and this translated to high standard deviations in the M2 counts in both samples. In a recent study by Cen *et* *al*[2], which used a larger sample (mutated patients: 110, wild-type patients: 798) from the Cancer Genomic Atlas and the Gene Expression Omnibus databases, the authors reported a higher immune cell infiltration and lower tumor purity. Specifically, a higher proportion of CD8+ T cells, M1 macrophages as well as neutrophils were found in BRAFV600E-mutated CRC patients, whereas no difference was found in M2 macrophage levels. Furthermore, according to the consensus molecular subtypes’ classification, which provides the most comprehensive description of CRC heterogeneity at the gene expression level, BRAFV600E mutation is associated with consensus molecular subtype 1, which correlates with high immune infiltration and immune-response pathway activity[3].

Interestingly, subtypes of BRAFV600E based on expression patterns in CRC have been further identified. There are two subtypes regardless of microsatellite instability, PI3K mutation status, sex and sidedness: BM1 and BM2[4]. Differences between those subtypes exist, including the prognosis (BM1 was found to have a poorer prognosis than BM2) and the immune status. BM1 has an overall stronger immune profile, emphasized by the activation of pathways like IL2/STAT5, tumor necrosis factor-α signaling *via* nuclear factor kappa B, IL6/JAK/STAT3 and allograft rejection[4]. Taking these subtypes into consideration will reveal a deeper understanding of the tumor immune microenvironment in BRAF-mutated CRC patients.

The immune status of the tumor microenvironment is a multilayered complex subject that leads to crucial implications regarding tumor cell immune evasion, therapeutic response or distant invasion tendency. Therefore, we feel that limiting the immune landscape to the levels of tumor-associated macrophages (M1/2) and cancer-associated fibroblasts, as in the study by Zhi *et al*[1], would not reflect the whole story. This is particularly due to the fact that other key immune components, such as CD8+ and CD4+ T cells, neutrophils, myeloid-derived suppressor cells and regulatory T cells, were not investigated. Of note, higher levels of cytotoxic CD8+ T cells could possibly be neutralized in the tumor microenvironment by immune checkpoints, such as programmed death protein and its ligand or cytotoxic T lymphocyte-associated protein 4[5]. In addition, microsatellite status is of paramount importance in this context, since a higher abundance of CD8+ T cells, activated natural killer cells and M1 macrophages, and upregulated immune checkpoints were identified in microsatellite instability compared to microsatellite-stable CRC[6]. Hence, future investigations including a wider array of immune components, taking into consideration significant genomic features (microsatellite instability and tumor mutational burden), will likely shed light on more reflective findings into the tumor immune status.

In conclusion, the authors presented compelling findings that provide a new perspective on BRAFV600E-mutated CRC immune microenvironment by discussing a proposed mechanism for inducing an immunosuppressed state through the release of exosomal long noncoding RNAs. Future studies targeting this topic should take into consideration the entire spectrum of the dynamic immune activity in the tumor microenvironment, covering relevant immune cells, immune checkpoints and molecular aberrations. Such comprehensive studies will provide insight for promising therapeutic opportunities for this subset of CRC patients.

**REFERENCES**

1 **Zhi J**, Jia XJ, Yan J, Wang HC, Feng B, Xing HY, Jia YT. BRAFV600E mutant colorectal cancer cells mediate local immunosuppressive microenvironment through exosomal long noncoding RNAs. *World J Gastrointest Oncol* 2021; **13**: 2129-2148 [PMID: 35070047 DOI: 10.4251/wjgo.v13.i12.2129]

2 **Cen S**, Liu K, Zheng Y, Shan J, Jing C, Gao J, Pan H, Bai Z, Liu Z. BRAF Mutation as a Potential Therapeutic Target for Checkpoint Inhibitors: A Comprehensive Analysis of Immune Microenvironment in BRAF Mutated Colon Cancer. *Front Cell Dev Biol* 2021; **9**: 705060 [PMID: 34381786 DOI: 10.3389/fcell.2021.705060]

3 **Dienstmann R**, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. *Nat Rev Cancer* 2017; **17**: 79-92 [PMID: 28050011 DOI: 10.1038/nrc.2016.126]

4 **Barras D**, Missiaglia E, Wirapati P, Sieber OM, Jorissen RN, Love C, Molloy PL, Jones IT, McLaughlin S, Gibbs P, Guinney J, Simon IM, Roth AD, Bosman FT, Tejpar S, Delorenzi M. BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression. *Clin Cancer Res* 2017; **23**: 104-115 [PMID: 27354468 DOI: 10.1158/1078-0432.CCR-16-0140]

5 **Rosenbaum MW**, Bledsoe JR, Morales-Oyarvide V, Huynh TG, Mino-Kenudson M. PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. *Mod Pathol* 2016; **29**: 1104-1112 [PMID: 27198569 DOI: 10.1038/modpathol.2016.95]

6 **Bao X**, Zhang H, Wu W, Cheng S, Dai X, Zhu X, Fu Q, Tong Z, Liu L, Zheng Y, Zhao P, Fang W, Liu F. Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy. *J Immunother Cancer* 2020; **8** [PMID: 33028695 DOI: 10.1136/jitc-2020-001437]

**Footnotes**

**Conflict-of-interest statement:** Saeed A reports research grants from AstraZeneca, Bristol Myers Squibb, Merck, Exelixis, KAHR Medical, and Incyte, and advisory board fees from AstraZeneca, Bristol Myers Squibb, Merck, Exelixis, and Pfizer. The other authors report no conflicts of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Corresponding Author's Membership in Professional Societies:** American Society of Clinical Oncology.

**Peer-review started:** January 27, 2022

**First decision:** April 17, 2022

**Article in press:**

**Specialty type:** Oncology

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Liu Z, China; Xiao T, China **A-Editor:** Lin (Online Science Editor) FY, China **S-Editor:** Fan JR **L-Editor:** A **P-Editor:** Fan JR